UNLIMITED TURBO BULL - ASTRAZENECA | Real-time Euronext Paris 11:49:59 29/05/2024 BST | ||
| 2.175 EUR | -1.58% |
|
| Current month | -1.78% | ||
| 1 month | -5.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 2.175 | -1.58% |
| 28/05/24 | 2.21 | -13.84% |
| 27/05/24 | 2.565 | +0.20% |
| 24/05/24 | 2.56 | -4.48% |
| 23/05/24 | 2.68 | +5.51% |
Real-time Euronext Paris
Last update May 29, 2024 at 11:49 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 8V39S | |
| ISIN | DE000SW9DHQ7 |
| Date issued | 23/04/2024 |
| Strike | 10,182 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.705 € |
|---|---|
| Lowest since issue | 1.365 € |
| Spread | 0.01 € |
| Spread % | 0.46% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Certificates
- 8V39S Certificat
